Skip to content

Integrated Biosciences — Small-molecule drugs for age-related diseases

Recently funded· $68.4M· August 5, 2026

Integrated Biosciences is a biotechnology company specializing in synthetic biology and machine learning to develop advanced therapeutics for age-related diseases. Founded in 2022, the company focuses on innovative drug discovery methods, utilizing AI and synthetic biology to increase efficiency in drug development. Its cutting-edge approach allows for the identification and modulation of biological pathways, alongside the discovery of novel small-molecule drug candidates. The company's mission is to achieve healthier human aging through scientific advancements.

Get it by email

Companies like Integrated Biosciences go out every weekday morning. One-click unsubscribe.

Agent? Subscribe over MCP

Round
$68.4M
Sectors
Biotechnology, Artificial intelligence, Therapeutics, Machine learning
Logged
August 5, 2026, in issue #5

More in biotechnology and artificial intelligence

Integrated Biosciences went out in issue #5, with 7 other picks.